{"id":1236,"text":"The aim of this open-label, fixed-sequence study was to investigate the potential of Echinacea purpurea, a commonly used botanical supplement, to interact with the boosted protease inhibitor darunavir-ritonavir.","label":[[16,48,"Study"],[85,103,"Herb name"],[160,210,"Drug"]],"Comments":[]}
{"id":1237,"text":"Fifteen HIV-infected patients receiving antiretroviral therapy including darunavir-ritonavir (600\/100 mg twice daily) for at least 4 weeks were included.","label":[[0,29,"Cohort"],[8,20,"Pathology"],[40,92,"Drug"],[94,104,"Amount"],[105,116,"Frequency"],[118,138,"Duration"]],"Comments":[]}
{"id":1238,"text":"E. purpurea root extract capsules were added to the antiretroviral treatment (500 mg every 6 h) from days 1 to 14.","label":[[0,11,"Herb name"],[0,33,"Extraction process"],[12,16,"Herb part"],[78,84,"Amount"],[78,94,"Frequency"],[96,113,"Duration"]],"Comments":[]}
{"id":1239,"text":"Darunavir concentrations in plasma were determined by high-performance liquid chromatography immediately before and 1, 2, 4, 6, 8, 10, and 12 h after a morning dose of darunavir-ritonavir on days 0 (darunavir-ritonavir) and 14 (darunavir-ritonavir plus echinacea).","label":[[0,9,"Drug"],[0,34,"Parameter"],[116,149,"Duration"],[168,187,"Drug"],[199,218,"Drug"],[228,247,"Drug"],[253,262,"Herb name"]],"Comments":[]}
{"id":1240,"text":"Individual darunavir pharmacokinetic parameters were calculated by noncompartmental analysis and compared between days 0 and 14 with the geometric mean ratio (GMR) and its 90% confidence interval (CI).","label":[[11,20,"Drug"],[106,127,"Duration"]],"Comments":[]}
{"id":1241,"text":"The median age was 49 (range, 43 to 67) years, and the body mass index was 24.2 (range, 18.7 to 27.5) kg\/m","label":[[19,45,"Age"],[51,70,"Parameter"],[75,106,"Amount"]],"Comments":[]}
